phrykt

Treace Medical Concepts, Inc. (TMCI): who owns it and who trades it

As of Nov 16, 2026, TMCI insiders reported 14 purchases worth $1.5M in the last 12 months. The largest buyer was John T. Treace (CEO), with $1.5M. 4 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Treace Medical Concepts

From the latest filings

Overall: more buying than selling. Insiders and famous investors mostly bought. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns TMCI

118 funds and institutions reported TMCI shares worth $128M at the end of Q2 2026, about 50% of the company. The largest holder is Armistice Capital, LLC with 9.8%.

Funds and institutions (13F) 50%Everyone else 50%

10 largest owners, by share of the company

Armistice Capital, LLC9.8%
Bank of America Corp5.1%
Gagnon Securities LLC4.7%
Vanguard Capital Management LLC3.1%
Gagnon Advisors, LLC2.4%
AQR Capital Management LLC2.3%
BlackRock, Inc.2.1%
Marshall Wace, LLP2.0%
CIBC Bancorp USA Inc.1.9%
Acadian Asset Management LLC1.4%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Armistice Capital, LLC6.36M9.81%$25.3MNo change
Bank of America Corp3.31M5.09%$13.2M+3%
Gagnon Securities LLC3.03M4.67%$12.1M-42%
Vanguard Capital Management LLC2.03M3.13%$8.1M+39%
Gagnon Advisors, LLC1.53M2.36%$6.1M–
AQR Capital Management LLC1.50M2.31%$6M+41%
BlackRock, Inc.1.38M2.13%$5.5M-59%
Marshall Wace, LLP1.33M2.05%$5.3M+401%
CIBC Bancorp USA Inc.1.22M1.87%$4.8M-0%
Acadian Asset Management LLC928,1771.43%$3.7M-1%
Millennium Management LLC738,6281.14%$2.9M-36%
Weber Capital Management LLC589,6170.91%$2.3MNo change
D. E. Shaw & Co., Inc.583,2770.90%$2.3M-31%
Geode Capital Management, LLC573,7960.88%$2.3M-43%
Citadel Advisors LLC516,9940.80%$2.1M-37%
Goldman Sachs Group Inc492,1160.76%$2M+27%
Stifel Financial Corp435,0090.67%$1.7M+147%
UBS Group AG366,4450.56%$1.5M-33%
Jacobs Levy Equity Management, Inc363,7290.56%$1.4M+38%
Raymond James Financial Inc331,1100.51%$1.3M-7%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, TMCI insiders reported $1.5M of open-market purchases and $0 of sales.

Purchases, 12 months
$1.5M
14 trades, 1 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
Aug 24, 2026
Filed Aug 24, 2026

Purchases and sales by month

$716K$716KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Aug 24, 2026John T. TreaceCEOPurchase11,000$4.34$47.7KForm 4
Aug 21, 2026John T. TreaceCEOPurchase5,000$4.35$21.8KForm 4
Aug 20, 2026John T. TreaceCEOPurchase39,944$4.44$177KForm 4
Jun 11, 2026John T. TreaceCEOPurchase9,891$4.04$40KForm 4
Jun 11, 2026John T. TreaceCEOPurchase22,887$4.04$92.5KForm 4
Jun 10, 2026John T. TreaceCEOPurchase14,715$4.02$59.2KForm 4
Jun 10, 2026John T. TreaceCEOPurchase29,430$4.02$118KForm 4
Jun 1, 2026John T. TreaceCEOPurchase50,000$3.56$178KForm 4
May 28, 2026John T. TreaceCEOPurchase61,202$3.02$185KForm 4
May 27, 2026John T. TreaceCEOPurchase49,810$2.87$143KForm 4
May 26, 2026John T. TreaceCEOPurchase4,508$2.79$12.6KForm 4
May 14, 2026John T. TreaceCEOPurchase61,750$2.62$162KForm 4
May 13, 2026John T. TreaceCEOPurchase49,013$2.46$121KForm 4
May 12, 2026John T. TreaceCEOPurchase43,000$2.17$93.3KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
John T. TreaceChief Executive Officer, Director, 10% owner$1.5M–Aug 24, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

TMCI short interest

Low short interest. 2.7% of TMCI shares are sold short: about 1 share in 37. Over the last 12 reports the number of shares short went down 50%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 1.79M TMCI shares were sold short, 2.7% of the shares outstanding, down 6.9% from the report before. At the average daily volume of 206,951 shares, buying them all back would take about 8.7 trading days (days to cover).

Shares short, % of all shares

2.73%May 15Oct 306.92%

Days to cover

8.7May 15Oct 309.8

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20261.79M2.73%-7%206,9518.7
Oct 15, 20261.92M2.96%-3%230,7868.3
Sep 30, 20261.98M3.04%+14%229,9428.6
Sep 15, 20261.74M2.67%+11%205,2558.5
Aug 31, 20261.56M2.40%-2%291,7755.3
Aug 14, 20261.60M2.45%-6%537,5313.0
Jul 31, 20261.70M2.61%-8%310,9245.5
Jul 15, 20261.84M2.84%+6%515,1773.6
Jun 30, 20261.75M2.70%-47%1.69M1.0
Jun 15, 20263.27M5.04%-20%721,9514.5
May 29, 20264.11M6.33%+14%559,9337.3
May 15, 20263.61M5.57%-9%581,6886.2

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Treace Medical Concepts company events

Treace Medical Concepts filed 8 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Nov 6, 2026.

  1. Nov 6, 2026ResultsReleased financial results. Filing
  2. Aug 7, 2026ResultsReleased financial results. Filing
  3. May 20, 2026VoteReported shareholder vote results. Filing
  4. May 8, 2026ResultsReleased financial results. Filing
  5. Apr 9, 2026LeadershipEffective as of the close of business on April 8, 2026, Gaetano M. Guglielmino, Chief Commercial Officer of Treace Medical Concepts, Inc., will depart from the Company. Filing
  6. Feb 27, 2026ResultsReleased financial results. Filing
  7. Jan 13, 2026ResultsReleased financial results. Filing
  8. Dec 18, 2025AgreementTreace Medical Concepts, Inc. entered into (1) a Loan and Security Agreement with SLR Investment Corp. and the lenders thereto, and (2) a Credit Agreement (the “Revolving Loan Agreement” and collectively with the Term Loan Agreement, the “Loan Agreements”) with Gemino Healthcare Finance, LLC d/b/a… Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Treace Medical Concepts financials

Famous investors that hold TMCI

4 of the 50 well-known investors we track reported holding TMCI in their latest 13F filing. The largest position is Israel Englander's, worth $5.5M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Israel Englander · Millennium ManagementQ3 20261.25M$5.5M0.0%+69%
Ken Griffin · Citadel AdvisorsQ3 2026287,955$1.3M0.0%-44%
Steve Cohen · Point72 Asset ManagementQ3 202682,917$368K0.0%New
Jim Simons · Renaissance TechnologiesQ3 202652,600$234K0.0%+9%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named TMCI in the last 120 days.

FiledHolderFormStake
Nov 16, 2026Armistice Capital, LLC13G9.8%
Nov 16, 2026Armistice Capital, LLC13G9.8%
Nov 16, 2026Armistice Capital, LLC13G/A2.0%
Nov 16, 2026Armistice Capital, LLC13G/A2.0%

Questions about Treace Medical Concepts, Inc. (TMCI) stock

Who owns the most TMCI stock?

The largest reported owner of Treace Medical Concepts, Inc. (TMCI) is Armistice Capital, LLC, with 9.8% of the company. In total, 118 funds and institutions reported holding TMCI at the end of Q2 2026, together about 50% of the shares. See the largest owners.

Are TMCI insiders buying or selling?

In the last 12 months, TMCI insiders reported 14 open-market purchases worth $1.5M and no sales. The latest trade was on Aug 24, 2026. See every trade.

What is the short interest in TMCI?

As of Oct 30, 2026, 1.79M TMCI shares were sold short, 2.7% of the shares outstanding, down 6.9% from the report before. At the average daily volume of 206,951 shares, buying them all back would take about 8.7 trading days (days to cover). See the history.

Which famous investors hold TMCI?

4 of the 50 well-known investors we track reported TMCI in their latest 13F filing, including Israel Englander, Ken Griffin, Steve Cohen. The largest position is worth $5.5M. See all holders.

Executive pay

Treace Medical Concepts's chief executive was paid a total of $5.4M for the year ended Dec 31, 2025, down 18% from $6.6M the year before. In the last 12 months, Treace Medical Concepts's executives and directors bought $1.5M of stock on the open market and sold none.

Chief executive, total pay$5.4MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Other top executives, average$3.1MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.